
ILC Therapeutics
Engineered hybrid interferons for viral and inflammatory diseases.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor investor investor | €0.0 | round | |
* | £2.5m Valuation: £17.5m | Early VC | |
Total Funding | 000k |
GBP | 2016 | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | - | - | 317 % | (126 %) | - |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | - | - | - | 631 % | 444 % | (4651 %) | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | - | - | 549 % | 408 % | (4205 %) | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
ILC Therapeutics is a UK-based biotechnology company that engineers hybrid interferons, a novel class of drugs with potentially improved therapeutic profiles. The company was founded in 2012 by Professor William H. Stimson, who also established the Department of Immunology at The University of Strathclyde, and Alistair Strachan. Professor Stimson's research into interferon subtypes and their roles as immunoregulators and antivirals led to the creation of the company's core technology.
The company's business model is centered on its proprietary platform technology which designs and develops novel hybrid interferons for diseases with significant unmet medical needs. Their commercial strategy involves seeking co-development and licensing partners for their assets as they advance through clinical stages. ILC Therapeutics operates as a semi-virtual company, utilizing external contract research and manufacturing organizations while conducting research at its own laboratory facilities near Glasgow.
Their lead product candidate, Alfacyte™, is a synthetic, broad-spectrum antiviral developed from the most effective alpha interferon subtypes. It is being developed as a therapeutic for respiratory viral infections, including Respiratory Syncytial Virus (RSV) and potential future pandemic threats like coronaviruses. Alfacyte™ is designed to have enhanced efficacy and reduced toxicity, potentially avoiding the flu-like symptoms associated with natural interferon treatments. A second candidate, Dermacyte™, targets inflammatory skin conditions like atopic dermatitis. The company has secured multiple rounds of funding, including investments from Scottish Enterprise, Eos Advisory, and Medical Incubator Japan, to advance its candidates through pre-clinical and clinical development.
Keywords: hybrid interferons, cytokine engineering, antiviral therapeutics, innate immune system, respiratory viral infections, Alfacyte, immunomodulation, biopharmaceutical, drug development, atopic dermatitis, preclinical development, respiratory syncytial virus, RSV, interferon alpha, viral diseases, inflammatory diseases, clinical trials, broad-spectrum antiviral